Publications by authors named "R Frank Chandler"
Determining recombinant AAV capsid extracellular and intracellular biodistribution by dual radioisotope labeling.
Mol Ther Methods Clin Dev
December 2024
Article Synopsis
- - The HEALing Communities Study (HCS) aimed to reduce opioid overdose deaths in 67 affected communities by implementing health campaigns focused on opioid use disorder (OUD), overdose prevention, and stigma reduction, developed with community input.
- - Surveys conducted via Facebook/Instagram indicated that participants in HCS communities experienced reduced stigma related to OUD and improved beliefs about the efficacy of naloxone, though recognition of campaign messages was not significantly different from control communities.
- - The study suggests a connection between recognizing campaign messages and achieving positive outcomes, but it also raises concerns about the effectiveness of traditional evaluation methods for social media health campaigns.
Background And Objective: Apalutamide (APA) is a treatment for metastatic castration-sensitive prostate cancer (mCSPC). In the ARON-3 study we investigated real-world experiences with APA treatment for mCSPC.
Methods: We retrospectively assessed real-world clinical outcomes for patients with mCSPC treated with APA in the ARON-3 study.
Aim: Psychosis is associated with significant health and societal costs. Early intervention in psychosis services (EIP) are highly effective in promoting recovery, yet substantial proportions of young people disengage. The current study aimed to develop and evaluate a novel engagement intervention in EIP services.
View Article and Find Full Text PDFImportance: The HEALing Communities Study (HCS) evaluated the effectiveness of the Communities That HEAL (CTH) intervention in preventing fatal overdoses amidst the US opioid epidemic.
Objective: To evaluate the impact of the CTH intervention on total drug overdose deaths and overdose deaths involving combinations of opioids with psychostimulants or benzodiazepines.
Design, Setting, And Participants: This randomized clinical trial was a parallel-arm, multisite, community-randomized, open, and waitlisted controlled comparison trial of communities in 4 US states between 2020 and 2023.